DocDollars

Ipsen Biopharmaceuticals, Inc

MA · United States · Reporting entity ID 100000000123

Total reported 2019–2025
$102.0M
#92 of 2,960 reporting companies — 0.1% of all reported industry payments
$20.0M in general payments across 82,935 records, plus $82.0M in research funding across 1,651 records.

How it breaks down

General payments $20,010,178
Research funding $82,031,733

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Ipsen Biopharmaceuticals, Inc reported $102.0M to US doctors and teaching hospitals from 2019 to 2025, ranking #92 of 2,960 reporting companies. 80% of that was research funding and 20% general payments such as consulting, speaking, food and travel. 82,935 general payment records and 1,651 research records were filed.

Common questions about Ipsen Biopharmaceuticals, Inc

How much has Ipsen Biopharmaceuticals, Inc paid US doctors?

Ipsen Biopharmaceuticals, Inc reported $102,041,911 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $20,010,178 in general payments, $82,031,733 in research funding.

How does Ipsen Biopharmaceuticals, Inc rank among drug and device companies?

It ranks #92 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Ipsen Biopharmaceuticals, Inc mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.